Search Results - "Leukemia"

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms by Khoury, Joseph D., Solary, Eric, Abla, Oussama, Akkari, Yassmine, Alaggio, Rita, Apperley, Jane F., Bejar, Rafael, Berti, Emilio, Busque, Lambert, Chan, John K. C., Chen, Weina, Chen, Xueyan, Chng, Wee-Joo, Choi, John K., Colmenero, Isabel, Coupland, Sarah E., Cross, Nicholas C. P., De Jong, Daphne, Elghetany, M. Tarek, Takahashi, Emiko, Emile, Jean-Francois, Ferry, Judith, Fogelstrand, Linda, Fontenay, Michaela, Germing, Ulrich, Gujral, Sumeet, Haferlach, Torsten, Harrison, Claire, Hodge, Jennelle C., Hu, Shimin, Jansen, Joop H., Kanagal-Shamanna, Rashmi, Kantarjian, Hagop M., Kratz, Christian P., Li, Xiao-Qiu, Lim, Megan S., Loeb, Keith, Loghavi, Sanam, Marcogliese, Andrea, Meshinchi, Soheil, Michaels, Phillip, Naresh, Kikkeri N., Natkunam, Yasodha, Nejati, Reza, Ott, German, Padron, Eric, Patel, Keyur P., Patkar, Nikhil, Picarsic, Jennifer, Platzbecker, Uwe, Roberts, Irene, Schuh, Anna, Sewell, William, Siebert, Reiner, Tembhare, Prashant, Tyner, Jeffrey, Verstovsek, Srdan, Wang, Wei, Wood, Brent, Xiao, Wenbin, Yeung, Cecilia, Hochhaus, Andreas

“…The upcoming 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours is part of an effort to hierarchically catalogue…”
Get full text

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms by Alaggio, Rita, Amador, Catalina, Anagnostopoulos, Ioannis, Attygalle, Ayoma D., Araujo, Iguaracyra Barreto de Oliveira, Berti, Emilio, Bhagat, Govind, Borges, Anita Maria, Boyer, Daniel, Calaminici, Mariarita, Chadburn, Amy, Chan, John K. C., Cheuk, Wah, Chng, Wee-Joo, Choi, John K., Chuang, Shih-Sung, Coupland, Sarah E., Czader, Magdalena, Dave, Sandeep S., de Jong, Daphne, Du, Ming-Qing, Elenitoba-Johnson, Kojo S., Ferry, Judith, Geyer, Julia, Gratzinger, Dita, Guitart, Joan, Gujral, Sumeet, Harris, Marian, Harrison, Christine J., Hartmann, Sylvia, Hochhaus, Andreas, Jansen, Patty M., Karube, Kennosuke, Kempf, Werner, Khoury, Joseph, Kimura, Hiroshi, Klapper, Wolfram, Kovach, Alexandra E., Kumar, Shaji, Lazar, Alexander J., Lazzi, Stefano, Leoncini, Lorenzo, Leung, Nelson, Leventaki, Vasiliki, Li, Xiao-Qiu, Lim, Megan S., Liu, Wei-Ping, Louissaint, Abner, Marcogliese, Andrea, Medeiros, L. Jeffrey, Michal, Michael, Miranda, Roberto N., Mitteldorf, Christina, Montes-Moreno, Santiago, Morice, William, Nardi, Valentina, Naresh, Kikkeri N., Natkunam, Yasodha, Ng, Siok-Bian, Oschlies, Ilske, Ott, German, Parrens, Marie, Pulitzer, Melissa, Rajkumar, S. Vincent, Rawstron, Andrew C., Rech, Karen, Rosenwald, Andreas, Said, Jonathan, Sarkozy, Clémentine, Sayed, Shahin, Saygin, Caner, Schuh, Anna, Sewell, William, Siebert, Reiner, Sohani, Aliyah R., Tooze, Reuben, Traverse-Glehen, Alexandra, Vega, Francisco, Vergier, Beatrice, Wechalekar, Ashutosh D., Wood, Brent, Xerri, Luc, Xiao, Wenbin

“…We herein present an overview of the upcoming 5 th edition of the World Health Organization Classification of Haematolymphoid Tumours focussing on lymphoid…”
Get full text

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia by Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., Hjorth-Hansen, H., Hughes, T. P., Janssen, J. J. W. M., Kantarjian, H. M., Kim, D. W., Larson, R. A., Lipton, J. H., Mahon, F. X., Mayer, J., Nicolini, F., Niederwieser, D., Pane, F., Radich, J. P., Rea, D., Richter, J., Rosti, G., Rousselot, P., Saglio, G., Saußele, S., Soverini, S., Steegmann, J. L., Turkina, A., Zaritskey, A., Hehlmann, R.

“…The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a…”
Get full text

Targeting FLT3 mutations in AML: review of current knowledge and evidence by Daver, Naval, Schlenk, Richard F., Russell, Nigel H., Levis, Mark J.

“…Genomic investigations of acute myeloid leukemia (AML) have demonstrated that several genes are recurrently mutated, leading to new genomic classifications,…”
Get full text

COVID-19 in persons with haematological cancers by He, Wenjuan, Chen, Lei, Chen, Li, Yuan, Guolin, Fang, Yun, Chen, Wenlan, Wu, Di, Liang, Bo, Lu, Xiaoting, Ma, Yanling, Li, Lei, Wang, Hongxiang, Chen, Zhichao, Li, Qiubai, Gale, Robert Peter

“…Infection with SARS-CoV-2, the cause of coronavirus infectious disease–19 (COVID-19), has caused a pandemic with >850,000 cases worldwide and increasing…”
Get full text

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy by Gandhi, Ujjawal H., Cornell, Robert F., Lakshman, Arjun, Gahvari, Zhubin J., McGehee, Elizabeth, Jagosky, Megan H., Gupta, Ridhi, Varnado, William, Fiala, Mark A., Chhabra, Saurabh, Malek, Ehsan, Mansour, Joshua, Paul, Barry, Barnstead, Alyssa, Kodali, Saranya, Neppalli, Amarendra, Liedtke, Michaela, Narayana, Swapna, Godby, Kelly N., Kang, Yubin, Kansagra, Ankit, Umyarova, Elvira, Scott, Emma C., Hari, Parameswaran, Vij, Ravi, Usmani, Saad Z., Callander, Natalie S., Kumar, Shaji K., Costa, Luciano J.

“…The introduction of CD38-targeting monoclonal antibodies (CD38 MoABs), daratumumab and isatuximab, has significantly impacted the management of patients with…”
Get full text

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study by Burger, Jan A., Barr, Paul M., Robak, Tadeusz, Owen, Carolyn, Ghia, Paolo, Tedeschi, Alessandra, Bairey, Osnat, Hillmen, Peter, Coutre, Steven E., Devereux, Stephen, Grosicki, Sebastian, McCarthy, Helen, Simpson, David, Offner, Fritz, Moreno, Carol, Dai, Sandra, Lal, Indu, Dean, James P., Kipps, Thomas J.

“…RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged…”
Get full text

Clinical use of lentiviral vectors by Milone, Michael C., O’Doherty, Una

“…Viral vectors provide an efficient means for modification of eukaryotic cells, and their use is now commonplace in academic laboratories and industry for both…”
Get full text

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome by Cortes, Jorge E., Heidel, Florian H., Hellmann, Andrzej, Fiedler, Walter, Smith, B. Douglas, Robak, Tadeusz, Montesinos, Pau, Pollyea, Daniel A., DesJardins, Pierre, Ottmann, Oliver, Ma, Weidong Wendy, Shaik, M. Naveed, Laird, A. Douglas, Zeremski, Mirjana, O’Connell, Ashleigh, Chan, Geoffrey, Heuser, Michael

“…Glasdegib is a Hedgehog pathway inhibitor. This phase II, randomized, open-label, multicenter study (ClinicalTrials.gov, NCT01546038) evaluated the efficacy of…”
Get full text

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches by Shah, Nina, Chari, Ajai, Scott, Emma, Mezzi, Khalid, Usmani, Saad Z.

“…Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a substantial proportion of patients do not respond to current…”
Get full text

Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity by Liu, E, Tong, Y, Dotti, G, Shaim, H, Savoldo, B, Mukherjee, M, Orange, J, Wan, X, Lu, X, Reynolds, A, Gagea, M, Banerjee, P, Cai, R, Bdaiwi, M H, Basar, R, Muftuoglu, M, Li, L, Marin, D, Wierda, W, Keating, M, Champlin, R, Shpall, E, Rezvani, K

“…Chimeric antigen receptors (CARs) have been used to redirect the specificity of autologous T cells against leukemia and lymphoma with promising clinical…”
Get full text

The MLL recombinome of acute leukemias in 2017 by Meyer, C, Burmeister, T, Gröger, D, Tsaur, G, Fechina, L, Renneville, A, Sutton, R, Venn, N C, Emerenciano, M, Pombo-de-Oliveira, M S, Barbieri Blunck, C, Almeida Lopes, B, Zuna, J, Trka, J, Ballerini, P, Lapillonne, H, De Braekeleer, M, Cazzaniga, G, Corral Abascal, L, van der Velden, V H J, Delabesse, E, Park, T S, Oh, S H, Silva, M L M, Lund-Aho, T, Juvonen, V, Moore, A S, Heidenreich, O, Vormoor, J, Zerkalenkova, E, Olshanskaya, Y, Bueno, C, Menendez, P, Teigler-Schlegel, A, zur Stadt, U, Lentes, J, Göhring, G, Kustanovich, A, Aleinikova, O, Schäfer, B W, Kubetzko, S, Madsen, H O, Gruhn, B, Duarte, X, Gameiro, P, Lippert, E, Bidet, A, Cayuela, J M, Clappier, E, Alonso, C N, Zwaan, C M, van den Heuvel-Eibrink, M M, Izraeli, S, Trakhtenbrot, L, Archer, P, Hancock, J, Möricke, A, Alten, J, Schrappe, M, Stanulla, M, Strehl, S, Attarbaschi, A, Dworzak, M, Haas, O A, Panzer-Grümayer, R, Sedék, L, Szczepański, T, Caye, A, Suarez, L, Cavé, H, Marschalek, R

“…Chromosomal rearrangements of the human MLL/KMT2A gene are associated with infant, pediatric, adult and therapy-induced acute leukemias. Here we present the…”
Get full text

MDM2 inhibition: an important step forward in cancer therapy by Konopleva, Marina, Martinelli, Giovanni, Daver, Naval, Papayannidis, Cristina, Wei, Andrew, Higgins, Brian, Ott, Marion, Mascarenhas, John, Andreeff, Michael

“…Targeting the interaction between tumor suppressor p53 and the E3 ligase MDM2 represents an attractive treatment approach for cancers with wild-type or…”
Get full text

COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey by Ljungman, Per, de la Camara, Rafael, Mikulska, Malgorzata, Tridello, Gloria, Aguado, Beatriz, Zahrani, Mohsen Al, Apperley, Jane, Berceanu, Ana, Bofarull, Rodrigo Martino, Calbacho, Maria, Ciceri, Fabio, Lopez-Corral, Lucia, Crippa, Claudia, Fox, Maria Laura, Grassi, Anna, Jimenez, Maria-Jose, Demir, Safiye Koçulu, Kwon, Mi, Llamas, Carlos Vallejo, Lorenzo, José Luis López, Mielke, Stephan, Orchard, Kim, Porras, Rocio Parody, Vallisa, Daniele, Xhaard, Alienor, Knelange, Nina Simone, Cedillo, Angel, Kröger, Nicolaus, Piñana, José Luis, Styczynski, Jan

“…This study reports on 382 COVID-19 patients having undergone allogeneic ( n  = 236) or autologous ( n  = 146) hematopoietic cell transplantation (HCT) reported…”
Get full text

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet by Barbui, Tiziano, Tefferi, Ayalew, Vannucchi, Alessandro M., Passamonti, Francesco, Silver, Richard T., Hoffman, Ronald, Verstovsek, Srdan, Mesa, Ruben, Kiladjian, Jean-Jacques, Hehlmann, Rȕdiger, Reiter, Andreas, Cervantes, Francisco, Harrison, Claire, Mc Mullin, Mary Frances, Hasselbalch, Hans Carl, Koschmieder, Steffen, Marchetti, Monia, Bacigalupo, Andrea, Finazzi, Guido, Kroeger, Nicolaus, Griesshammer, Martin, Birgegard, Gunnar, Barosi, Giovanni

“…This document updates the recommendations on the management of Philadelphia chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) published in 2011 by…”
Get full text

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis by Kantarjian, Hagop M., Hughes, Timothy P., Larson, Richard A., Kim, Dong-Wook, Issaragrisil, Surapol, le Coutre, Philipp, Etienne, Gabriel, Boquimpani, Carla, Pasquini, Ricardo, Clark, Richard E., Dubruille, Viviane, Flinn, Ian W., Kyrcz-Krzemien, Slawomira, Medras, Ewa, Zanichelli, Maria, Bendit, Israel, Cacciatore, Silvia, Titorenko, Ksenia, Aimone, Paola, Saglio, Giuseppe, Hochhaus, Andreas

“…In the ENESTnd study, with ≥10 years follow-up in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase, nilotinib demonstrated higher…”
Get full text

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma by Flores-Montero, J, Sanoja-Flores, L, Paiva, B, Puig, N, García-Sánchez, O, Böttcher, S, van der Velden, V H J, Pérez-Morán, J-J, Vidriales, M-B, García-Sanz, R, Jimenez, C, González, M, Martínez-López, J, Corral-Mateos, A, Grigore, G-E, Fluxá, R, Pontes, R, Caetano, J, Sedek, L, del Cañizo, M-C, Bladé, J, Lahuerta, J-J, Aguilar, C, Bárez, A, García-Mateo, A, Labrador, J, Leoz, P, Aguilera-Sanz, C, San-Miguel, J, Mateos, M-V, Durie, B, van Dongen, J J M, Orfao, A

“…Flow cytometry has become a highly valuable method to monitor minimal residual disease (MRD) and evaluate the depth of complete response (CR) in bone marrow…”
Get full text

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus by Scarfò, Lydia, Chatzikonstantinou, Thomas, Rigolin, Gian Matteo, Quaresmini, Giulia, Motta, Marina, Vitale, Candida, Garcia-Marco, Jose Antonio, Hernández-Rivas, José Ángel, Mirás, Fatima, Baile, Mónica, Marquet, Juan, Niemann, Carsten U., Reda, Gianluigi, Munir, Talha, Gimeno, Eva, Marchetti, Monia, Quaglia, Francesca Maria, Varettoni, Marzia, Delgado, Julio, Iyengar, Sunil, Janssens, Ann, Marasca, Roberto, Ferrari, Angela, Cuéllar-García, Carolina, Itchaki, Gilad, Špaček, Martin, De Paoli, Lorenzo, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Mauro, Francesca R., Šimkovič, Martin, Van Der Spek, Ellen, Vandenberghe, Elisabeth, Trentin, Livio, Wasik-Szczepanek, Ewa, Ruchlemer, Rosa, Bron, Dominique, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Farina, Lucia, Foglietta, Myriam, Gentile, Massimo, Herishanu, Yair, Herold, Tobias, Jaksic, Ozren, Kater, Arnon P., Kersting, Sabina, Malerba, Lara, Orsucci, Lorella, Popov, Viola Maria, Sportoletti, Paolo, Yassin, Mohamed, Pocali, Barbara, Barna, Gabor, Chiarenza, Annalisa, dos Santos, Gimena, Nikitin, Eugene, Andres, Martin, Dimou, Maria, Doubek, Michael, Enrico, Alicia, Hakobyan, Yervand, Kalashnikova, Olga, Ortiz Pareja, Macarena, Papaioannou, Maria, Rossi, Davide, Shah, Nimish, Shrestha, Amit, Stanca, Oana, Stavroyianni, Niki, Strugov, Vladimir, Tam, Constantine, Zdrenghea, Mihnea, Coscia, Marta, Stamatopoulos, Kostas, Rossi, Giuseppe, Rambaldi, Alessandro, Montserrat, Emili’, Foà, Robin, Cuneo, Antonio, Ghia, Paolo

“…Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more…”
Get full text

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis by Walker, Brian A., Mavrommatis, Konstantinos, Wardell, Christopher P., Ashby, T. Cody, Bauer, Michael, Davies, Faith, Rosenthal, Adam, Wang, Hongwei, Qu, Pingping, Hoering, Antje, Samur, Mehmet, Towfic, Fadi, Ortiz, Maria, Flynt, Erin, Yu, Zhinuan, Yang, Zhihong, Rozelle, Dan, Obenauer, John, Trotter, Matthew, Auclair, Daniel, Keats, Jonathan, Bolli, Niccolo, Fulciniti, Mariateresa, Szalat, Raphael, Moreau, Phillipe, Durie, Brian, Stewart, A. Keith, Goldschmidt, Hartmut, Raab, Marc S., Einsele, Hermann, Sonneveld, Pieter, San Miguel, Jesus, Lonial, Sagar, Jackson, Graham H., Anderson, Kenneth C., Avet-Loiseau, Herve, Munshi, Nikhil, Thakurta, Anjan, Morgan, Gareth

“…Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need of new treatment strategies to improve the outcomes. Multiple…”
Get full text

Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis by Li, Huan, Chen, Chongxiang, Hu, Fang, Wang, Jiaojiao, Zhao, Qingyu, Gale, Robert Peter, Liang, Yang

“…We performed a meta-analysis to determine safety and efficacy of corticosteroids in SARS-CoV-2, SARS-CoV, and MERS-CoV infections. We searched PubMed, Web of…”
Get full text